StatSure Diagnostic Systems, Inc.
(OTCBB: SSUR)
View the StockGuru Profile:
http://www.stockguru.com/profiles/ssur/
StatSure Diagnostic Systems, Inc.
StatSure Diagnostic Systems, Inc. (OTCBB: SSUR) is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral-fluid collection devices. The Company’s proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company’s diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.
Products
StatSure™ is a self-contained, rapid whole-blood testing format for the detection of antibodies to a broad spectrum of infectious disease targets. The sample is obtained though a small (~3µl) finger-stick. Results can often be read within several minutes and do not require any instrumentation. This product line is designed for on-site testing in clinics, doctors’ offices, the military,mobile health vans, emergency situations, and those places where immediate results are necessary. All SDS rapid tests (StatSure™ & StatSimple™) require no special handling, mixing, storage, electricity, refrigeration or specialized training. (US Patent #5,935,864)
StatSure™ HIV is a self-contained, rapid whole-blood test for the detection of HIV antibodies from a sample obtained though a small (~3µl) finger-stick. Results can often be read within several minutes and do not require any instrumentation. This kit is designed for on-site testing in clinics, doctors’ offices, mobile health vans, the military, emergency situations, and those places where immediate results are necessary. StatSure™ HIV is not currently available in the USA
Saliva•Sampler™ Saliva Collection Device
Saliva•Sampler™ is the only collection device available that offers a built-in Sample Volume Indicator, that creates a blue mark when sufficient sample has been obtained. The unique design of this product also eliminates a potentially time-consuming, manual step – centrifugation- and offers a quick, convenient, dignified, and painless alternative for gathering oral fluids.
Oral fluid tests are cost effective, easy to administer and eliminates adulteration and/or substitution. Sample collection with an oral fluid device is an improvement over collecting urine both in terms of employee dignity and the reduction of time employees spend away from the job. Plus, an observer can witness the employee collecting his or her own sample of saliva to prevent sample tampering. When an employee goes for a urine-based drug test, between two and two-and-half hours of an employee’s productive time and of the human resources staff member’s time is lost because the employee has to be accompanied to the off-site testing location. Oral fluid collection allows the employer to simply test the employee in the human resources office, and within 15 minutes, the employee is back on the job. Another benefit that oral fluid collection provides is that it eliminates adulteration and/or substitution. With urine tests, employees can adulterate or substitute their urine sample, but because oral fluid collecting is a self-administered, observed test that never leaves the employee’s hand, the test cannot be altered in anyway.
Patents and Trademarks
SDS is the owner of the following United States patents.
StatSure Hemastrip
#5,935,864
Method and kit for collecting samples of liquid specimens for analytical testing
August 10, 1999
Oral Fuid Collection Device
#5,260,031
Saliva sampling device with sample adequacy indicating system
November 9, 1993
#5,393,496
Saliva sampling device and sample adequacy system
February 28, 1995
#5,283,038
Fluid sampling and testing device
February 1, 1994
#5,268,148
Saliva sampling device and sample adequacy system
December 7, 1993
SDS Trademarks
* StatSure™
* SeroStrip™
* StatSimple™
Management
Steven M. Peltzman Chairman of the Board of Directors and Chief Executive Officer
Mr. Peltzman has more than thirty years of business experience in technology-based, health-care companies. In 1984, he helped start and served as President and CEO of Applied biotechnology, Inc. whose cancer business was sold to OSI Pharmaceuticals, Inc. in 1991, when he became Chief Operating Officer of the consolidated entity; from 1994 through 1997 he served as President and COO of OSIP and remained on its Board of Directors through 1999. From 1980 to 1984, Mr. Peltzman held senior executive positions with Millipore and for ten years preceding that was with Corning Glass Works’ Medical diagnostic and device businesses. During the past several years he has been active in several small health care and technology start-ups as their interim CEO or COO or in an advisory capacity to their Boards of Directors.
D. Bruce Pattison President and Chief Operating Officer
Mr. Pattison has over thirty years experience with technology based, health-care companies serving both diagnostic and therapeutic market segments. During the 1970’s he held several senior management positions with the medical diagnostic and device division of Corning Glass Works. After leaving Corning , Mr. Pattison was President of three start-up companies involved with innovative drug-delivery products. At the Infusaid Corporation during the 1980’s, Mr. Pattison led the regulatory approval and commercialization of two unique medical products: the industry’s first implantable pump and the first vascular access port. Most recently, Mr. Pattison negotiated the sale of Arrow International’s drug delivery business to Johnson & Johnson and then joined J&J as Executive Director of Drug Delivery.
Leo Ehrlich Chief Financial Officer
Leo Ehrlich was appointed to the Board of Directors in September 1999. In May of 2005, Mr Ehrlich was appointed Chief Financial Officer. Mr Ehrlich is a Certified Public Accountant and received his BBA from Bernard Baruch College of the City University of New York.
Joseph Levi
Joseph Levi was appointed to the Board of Directors in September 1999. Mr. Levi began his career as a systems engineer for ITT Avionics where he participated in the design of military communications systems. Subsequently, Mr. Levi was a software engineer at SIAC where he developed trading systems for the NYSE floor. Mr. Levi then held senior sales and marketing positions for various computer consulting firms. In 1991, Mr. Levi founded CompuNet Solutions which focused on selling computer equipment and consulting services to Fortune 2000 customers. Since 1995, Mr. Levi has practiced law at various top-tier New York law firms counseling technology clients on protecting, leveraging and enforcing their intellectual property rights. Mr. Levi is also the founder of Alleytech Ventures, LLC, an investment fund focusing on Internet technology investments. Mr. Levi has a BS in Electrical Engineering, summa cum laude, and an MS in Systems Engineering, both from Polytechnic University, and a JD from Brooklyn Law School, magna cum laude. Mr. Levi is registered to practice before the U.S. Patent and Trademark Office.
View the StockGuru Profile for
StatSure Diagnostic Systems:
http://www.stockguru.com/profiles/ssur/
We Invite you to Visit the All New StockGuru Blog!
Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.
Click HERE to visit the Blog, or go to:
http://stockguru.com/blog/
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4268. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $24,000 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.